Divergence among physicians over patient choice in biologics vs biosimilars

Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, revealing deep-rooted cultural and systemic differences.

While nearly half of (49%) physicians support patient involvement in treatment decisions, enthusiasm ranges from strong backing in China to notable skepticism in Germany and France - underscoring the growing but uneven shift toward shared decision-making in modern healthcare, finds pharma analytics company GlobalData.

GlobalData’s report, “Strategic Intelligence: Biosimilars - Through the Physician's Lens,” reveals that while the use of biosimilar continues to grow, the question of patient involvement in treatment decision has become increasingly relevant.